NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
April 13, 2004 • Volume 1 / Number 15 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Article

WHI Estrogen-Alone Data Indicate No Overall Benefit for Disease Prevention, No Apparent Increase in Cancer Risk

Data from the Women's Health Initiative (WHI) study to investigate the effect of estrogen-alone hormone replacement therapy (HRT) on the incidence of chronic disease indicate that there is no overall benefit for disease prevention. Specifically for cancer, it showed no effect on the risk of breast or colorectal cancer. Use of estrogen did, however, increase the risk of stroke by 39 percent, a finding that prompted the decision in February by the National Institutes of Health to bring the trial to a premature end. It was slated to run through March 2005. The trial's stoppage was initially announced in early March, but the complete data from the study were not published until this week in the Journal of the American Medical Association (JAMA).

Of particular interest to the cancer community is the finding that estrogen did not increase participants' risk of breast cancer during the study period. In fact, there was a trend, though not statistically significant, toward reduction in breast cancer incidence. Overall, 218 of the more than 10,000 postmenopausal women in the study - all of whom had undergone hysterectomy - developed breast cancer.  Read more  
Director's Update

CIRB to be Extended to Support Pediatric Trials

The annual spring meeting of the Children's Oncology Group (COG) was held in Washington, D.C., earlier this month, and I had the privilege of learning about some of the exciting work that COG researchers are currently conducting. Representative Bill Young (R-Fla.) and I had the honor of addressing the membership during its March 31 luncheon, when Rep. Young received the organization's Congressional Champion for Childhood Cancer Award in recognition of his pivotal role as Chair of the House Appropriations Committee and his leadership in supporting COG's research program to identify more effective treatments for children with cancer.

COG is a National Cancer Institute-supported clinical trials cooperative group devoted to translational and clinical research on childhood and adolescent cancers. It develops and coordinates clinical trials conducted through its 238 member institutions, which include cancer centers in the United States, Canada, Europe, and Australia. COG enrolls approximately 4,000 children and adolescents in treatment studies annually and has 70-80 studies open to patient accrual each year.  Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads a national effort to eliminate the suffering and death due to cancer. Through basic and clinical biomedical research and training, NCI conducts and supports research that will lead to a future in which we can prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit

NCI Cancer Bulletin staff can be reached at